WORLD HEALTH ORGANIZATION

The LODEFI study showed low-dose deferasirox effectively induced transfusion independence in low-risk MDS patients, with 47.4% achieving TI at 12 months. The treatment was well-tolerated, suggesting it could be a potential option for ESA-refractory or relapsing MDS patients with low transfusion burden.

GSK's DREAMM-7 trial shows belantamab mafodotin reduces death risk by 42% in multiple myeloma post-first relapse, with projected median OS of 84 months vs 51 months for daratumumab combination, and 3-year OS rate of 74% vs 60%. Therapy under regulatory review in seven major markets.

A Moroccan company, Moldiag, is producing mpox tests for African countries, addressing the continent's dependency on imported medical supplies highlighted during the COVID-19 pandemic. Moldiag's $5 tests are being sold to several African nations, aiming to provide affordable solutions. The Africa CDC has expedited approval for such tests, recognizing the need for rapid, locally produced diagnostics.

Achieve Life Sciences appoints Mark Oki as CFO to oversee financial strategy and operations, aiming to commercialize cytisinicline for nicotine dependence. Oki's experience in biopharma will support the potential first new treatment in two decades, addressing a global health crisis.

AI is transforming rehabilitation medicine with wearable sensors and risk prediction algorithms, offering personalized virtual fitness training and automated clinical assessments, though widespread deployment faces economic and privacy challenges.